Support funding for breakthrough innovation will help company’s development in preparation for clinical trials in bladder cancer
Funds will further development of a new cancer immunotherapy: synthetic TLR3 agonist TL-532.
Three senior industry executives join the board of directors.
A new dimension in immuno-oncology
41 quai Fulchiron
69005 Lyon, FRANCE